Artificial intelligence for digital and computational pathology

AH Song, G Jaume, DFK Williamson, MY Lu… - Nature Reviews …, 2023 - nature.com
Advances in digitizing tissue slides and the fast-paced progress in artificial intelligence,
including deep learning, have boosted the field of computational pathology. This field holds …

Revisiting neoadjuvant therapy in non-small-cell lung cancer

SPL Saw, BH Ong, KLM Chua, A Takano… - The Lancet …, 2021 - thelancet.com
Despite the rapidly evolving treatment landscape in advanced non-small-cell lung cancer
(NSCLC), developments in neoadjuvant and adjuvant treatments have been nascent by …

A population-level digital histologic biomarker for enhanced prognosis of invasive breast cancer

M Amgad, JM Hodge, MAT Elsebaie, C Bodelon… - Nature Medicine, 2024 - nature.com
Breast cancer is a heterogeneous disease with variable survival outcomes. Pathologists
grade the microscopic appearance of breast tissue using the Nottingham criteria, which are …

Human-interpretable image features derived from densely mapped cancer pathology slides predict diverse molecular phenotypes

JA Diao, JK Wang, WF Chui, V Mountain… - Nature …, 2021 - nature.com
Computational methods have made substantial progress in improving the accuracy and
throughput of pathology workflows for diagnostic, prognostic, and genomic prediction. Still …

Morphological and molecular breast cancer profiling through explainable machine learning

A Binder, M Bockmayr, M Hägele, S Wienert… - Nature Machine …, 2021 - nature.com
Recent advances in cancer research and diagnostics largely rely on new developments in
microscopic or molecular profiling techniques, offering high levels of detail with respect to …

Artificial intelligence to identify genetic alterations in conventional histopathology

D Cifci, S Foersch, JN Kather - The Journal of Pathology, 2022 - Wiley Online Library
Precision oncology relies on the identification of targetable molecular alterations in tumor
tissues. In many tumor types, a limited set of molecular tests is currently part of standard …

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer

J Liu, Y Wang, Z Tian, Y Lin, H Li, Z Zhu, Q Liu… - Nature …, 2022 - nature.com
In the later-line setting or for patients with PD-L1-negative tumors, immunotherapy-based
regimens remain ineffective against advanced triple-negative breast cancer (TNBC). In this …

The tale of TILs in breast cancer: a report from the international immuno-oncology biomarker working group

K El Bairi, HR Haynes, E Blackley, S Fineberg… - NPJ breast …, 2021 - nature.com
The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly
improved survival in several cancer settings. A subgroup of women with breast cancer (BC) …

Pitfalls in machine learning‐based assessment of tumor‐infiltrating lymphocytes in breast cancer: A report of the International Immuno‐Oncology Biomarker Working …

J Thagaard, G Broeckx, DB Page… - The Journal of …, 2023 - Wiley Online Library
The clinical significance of the tumor‐immune interaction in breast cancer is now
established, and tumor‐infiltrating lymphocytes (TILs) have emerged as predictive and …

The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast …

PI Gonzalez‐Ericsson, ES Stovgaard… - The Journal of …, 2020 - Wiley Online Library
Immune checkpoint inhibitor therapies targeting PD‐1/PD‐L1 are now the standard of care
in oncology across several hematologic and solid tumor types, including triple negative …